Paliperidone Krka

Paliperidone, the active ingredient in Paliperidone Krka, is an atypical antipsychotic presented as a tablet for oral use. It is indicated for the treatment of schizophrenia and schizoaffective disorder in adults.

GNH USA supplies Paliperidone Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways to manage psychotic disorders. - Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse. - Schizoaffective disorder: Alleviates mood‑related symptoms and psychotic features. - Maintenance therapy: Supports long‑term stability after an acute episode.

Paliperidone may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Akathisia: Restlessness and an urge to move. - Weight gain: Increased appetite leading to modest weight increase. - Somnolence: Drowsiness or fatigue. - Dry mouth: Reduced salivation. - Constipation: Slowed gastrointestinal motility. - Increased prolactin: Menstrual changes or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: Persistent involuntary movements. - Seizures: New‑onset or worsening of existing seizure disorder. - Orthostatic hypotension: Marked drop in blood pressure on standing. - Hyperglycaemia: Elevated blood glucose levels. - Cardiac arrhythmias: QT‑interval prolongation.

When prescribing Paliperidone, clinicians should evaluate patient‑specific factors and monitor for safety signals. - Cardiovascular assessment: Baseline ECG and blood pressure monitoring. - Metabolic monitoring: Periodic glucose and lipid panels. - Prolactin levels: Check for hyperprolactinemia symptoms. - Elderly patients: Use lower initial doses and monitor for falls. - Pregnancy and lactation: Weigh benefits against potential risks; avoid unless essential. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Paliperidone can interact with several drug classes, influencing its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors: May increase paliperidone exposure and toxicity. - CNS depressants: Combined sedation may be profound.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: Additive hypotensive effect. - Drugs that prolong QT interval: May increase arrhythmia risk. - CYP2D6 substrates: Potential for altered metabolism of co‑administered drugs.